Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes.

Slides:

Advertisements

Similar presentations

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

Advertisements

Stephanie J. Lee, Loretta A. Williams

A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation Imran Ahmad,

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging.

A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis Mohamed A. Kharfan-Dabaja,

Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker.

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease Sean Robinson.

Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis.

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation Kirsten.

National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established.

Stephanie J. Lee, Loretta A. Williams

Chronic graft-versus-host disease

Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease Areej El-Jawahri, Joseph Pidala,

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Clinical Benefit of Response in Chronic Graft-versus-Host Disease

Natural history of pulmonary complications in children after bone marrow transplantation Mark Eikenberry, Hana Bartakova, Todd Defor, Imad Y. Haddad,

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease Paul J. Martin, Barry.

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Measuring Therapeutic Response in Chronic Graft-versus-Host Disease

Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia Stella Santarone, Joseph Pidala, Marta.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical.

Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium.

Screening with Spirometry Is a Useful Predictor of Later Development of Noninfectious Pulmonary Syndromes in Patients Undergoing Allogeneic Stem Cell.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials Shernan G. Holtan, Todd.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802 by Shernan G. Holtan, Todd E. DeFor, Angela.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria Madan Jagasia, Jennifer Giglia, Wichai.

Jason W. Chien, Lue Ping Zhao, Barry Storer, Paul J

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Biology of Blood and Marrow Transplantation

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Presentation transcript:

Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease Jeanne Palmer, Kirsten Williams, Yoshihiro Inamoto, Xiaoyu Chai, Paul J. Martin, Linus H. Santo Tomas, Corey Cutler, Daniel Weisdorf, Brenda F. Kurland, Paul A. Carpenter, Joseph Pidala, Steven Z. Pavletic, William Wood, David Jacobsohn, Sally Arai, Mukta Arora, Madan Jagasia, Georgia B. Vogelsang, Stephanie J. Lee Biology of Blood and Marrow Transplantation Volume 20, Issue 3, Pages 337-344 (March 2014) DOI: 10.1016/j.bbmt.2013.11.025 Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Kaplan-Meier overall survival (left) and cumulative incidence of nonrelapse mortality (right), according to NIH symptom-based lung score at enrollment. Biology of Blood and Marrow Transplantation 2014 20, 337-344DOI: (10.1016/j.bbmt.2013.11.025) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Scatter plot (left) and Bland-Altman plot (right) between hand-held spirometry and FEV1 on PFTs. On the Bland-Altman plot, the mean difference between 2 measures was centered around zero (solid line), with the 95% limits of agreement shown by dashed lines. Biology of Blood and Marrow Transplantation 2014 20, 337-344DOI: (10.1016/j.bbmt.2013.11.025) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Spaghetti plot of hand-held spirometry FEV1 according to survival status. Biology of Blood and Marrow Transplantation 2014 20, 337-344DOI: (10.1016/j.bbmt.2013.11.025) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions